论文部分内容阅读
前列腺癌是西方国家男性发病率排位第一的恶性肿瘤,近年来我国前列腺癌的发病率也呈逐渐上升趋势。在晚期前列腺癌治疗中雄激素剥夺治疗成为首选和最重要的治疗措施,但大部分前列腺癌患者最终会进展为去势抵抗性前列腺癌。因此,研究者们一直在寻找在雄激素剥夺治疗基础上可以联用的方法以提高疗效。2004年,多西他赛被证明是第1个能改善晚期去势抵抗性前列腺癌患者生存的化学疗法药物。这样的结果使研究者们发起了多个多西他赛联合雄激素剥夺治疗晚期前列腺癌的临床研究。该文就这些相关临床研究及最新进展作了综述。
Prostate cancer is the number one malignant tumor in western countries, and the incidence of prostate cancer in China has also been on the rise. Androgen deprivation therapy is the treatment of choice and the most important treatment in the treatment of advanced prostate cancer, but most prostate cancer patients will eventually progress to castrate-resistant prostate cancer. As a result, researchers have been looking for ways to combine effects of androgen deprivation therapy to improve outcomes. In 2004, docetaxel proved to be the first chemotherapeutic drug to improve the survival of patients with advanced castrate-resistant prostate cancer. This result led researchers to initiate a multidose clinical trial of docetaxel in combination with androgen deprivation in the treatment of advanced prostate cancer. This article reviews these related clinical studies and recent developments.